リウマチ病セミナー VII

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

リウマチ病の診察で、専門医の最も関心の高い診断に関して多くの進歩が見られている。今回は最近の検査法に関するものをとりあげた。本年8月にリウマチ科の標榜が認可されたことにより、リウマチ患者を担当するリウマチ医にはリウマチ病全般についての幅広い知識と経験が要求されるようになるだろう。本セミナーが社会的な流れに沿ったものとして、今後一層役立つことを願ってやまない。（序文より）

目次

  • 表紙
  • 執筆者一覧
  • 序文
  • 目次
  • 炎症リウマチ
  • シリコンとリウマチ症状
  • リウマトイド結節
  • ベーチェット病の眼病変
  • アミロイドーシスと骨関節変化
  • SLE活動性のcriteria
  • RAの寛解
  • Livedo reticularis
  • 骨関節,脊椎,神経
  • 変形性関節症と性ホルモン
  • 骨軟骨疾患と遺伝子異常
  • 骨とビタミンK
  • 大転子部の痛み
  • 腰痛と生物活性物質
  • Osteosclerosis
  • 職業とリウマチ病
  • 検査法
  • 超音波法による骨量測定
  • 慢性関節リウマチの超音波検査
  • 慢性関節リウマチの生物学的マーカー
  • 生物学的反応
  • 筋運動エネルギー危機としての高尿酸血症
  • HLA-B27関連リウマチ性疾患における転写制御
  • リウマチ病とApoptosis
  • 治療と副作用
  • 骨疾患とBisphosphonate
  • 慢性関節リウマチの予防
  • RAと食事療法
  • 慢性関節リウマチにおけるメトトレキサートの作用機序
  • RAにおけるステロイド骨粗鬆症
  • RAに対する免疫療法の指標
  • 手術
  • RA足関節固定術
  • 頸椎のInstrumentation
  • 総目次
  • 索引
  • DRUG INFORMATION
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.10 掲載の参考文献
1) David AK: The basis of the FDA's decision on breast implants. The New Eng Med 326: 1713-1715, 1992.
 
2) Bridge AJ, et al: Silicone breast implants. History, Safety, and Potential complications. Arch Intern Med 153: 2638-2644, 1993
 
3) 三好和夫ら: 人体における Adjuvant 加遷延感作を思わせる高γグロブリン血症.日本醫事新報2122: 9-14, 1964
 
4) Kumagai Y, et al: Scleroderma after cometic surgery. Four cases of human adjuvant disease. Arthritis Rheum 2: 532-537, 1979
 
5) Jorge SG, et al: Silicone breast implants and rheumatic disease. Clinical, Immunologic, and Epidemiologic Studies. Artiritis Rheum 37: 158-168, 1994
 
6) Kaizer W, et al: Human adjuvant disease: remission of silicone induced autoimmune disease after explantation of breast augmentation. Ann Rheum Dis 49: 937-938, 1990
 
7) Britta OS, et al: Adjuvant breast disease: An evaluation of 100 symptomatic women with breast implants or silicone fluid injections. Keio J Med 43: 79-87, 1994
PubMed
8) Richard MS, et al: Demonstration of silicone in sites of connective-tissue disease in patients with silicone-gel brease implants. Arch Dermatol 129: 63-68, 1993
 
9) Suzanne ST, et al: Anti-collagen autoantibodies are found in women with silicone breast implants. J Autoimniun 6: 367-377, 1993
 
10) Randall MG, et al: Antibodies to silicone elastomers and reactions to ventriculopitoneal shunts. Lancet 340: 510-513, 1992
 
11) John ON, et al: The adjuvant effect of silicone-gel on antibody formation on rats. Immunol Invest 22: 151-161, 19
 
12) Leoncio G, et al: In vivo degradation of silicones, MRM 29: 839-843, 1993
 
P.17 掲載の参考文献
1) Kaye BR, Kaye RL, Bobrove A: Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med 76: 279-292, 1984.
PubMed
2) Tak-Dianant Z, Hooning Van Duyvenbode FJJ, et al: Intraarticular rheumatoid nodules a and triggering of the knee joint. Ann Rheum Dis 51: 533-535, 1992.
 
3) Shichikawa K, Matsui K, Oze K, et al: Rheumatoid pondylitis. International Orthopaedics (SICOT) 2: 53-60, 1978
 
4) Inoue K, Nishioka J, Hukuda S: Rheumatoid nodules at the cement-bone interface in revision arthroplasty of rheumatoid patients. J Bone Joint Surg 75B: 455-458, 1993.
 
5) Ziff M: The rheumatoid nodule. Arthritis Rheum 33: 761-767, 1990.
PubMed
6) Palmer DG, Hogg N, Allen CA, et al: A mononuclear pahgocyte subset asso ciated with cell necrosis in rheumatoid nodules: identification wtih monoclonal antibody 5.5. Clin Immunol Immunopathol 45: 17-28, 1987.
 
7) Palmer DG, Hogg N, Allen CA, et al: Macrophge migration and maturation within rheumatoid nodules. Arthritis Rheum 30: 729-736, 1987,
 
8) Duke OL, Hobbs S, Panayi GS, et al: A combined immunohistological and histochemical analysis of lymphocyte and macrophage subpopulations in the rheumatoid nodule. Clin Exp Immunol 56: 239-246, 1984.
PubMed
9) Gitlin D, Craig JM, Janeway C: Studies on the nature of fibrinoid in the collagen diseases. Am J Pathol 33: 55-57, 1957.
 
10) Vasquez JJ, Dixon FJ: Immunohistochemical study of lesions in rheumatic fever, systemic lupus erythematosus and rheumatoid arthritis, Lab Invest 6: 205-217, 1957.
 
11) Cohen PR, Kurzrock R: Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. Ann Rheum Dis 52: 685-688, 1993.
 
12) Olive A, Maymo J, Lloreta J, et al: Evolution of benign rheumatoid nodules into rheumatoid arthritis after 50 years. Ann Rheum Dis 46: 624-625, 1987
PubMed
13) Evans MJ, Blessing K, Gray E: Pseudorheumatoid nudule (deep granuloma annulare) of childhood: clinicopathologic features of twenty patients. Ped dermatol 11: 6-9, 1994.
 
14) Couret M, Combe B, Chuong VT, et al: Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. J Rheumatol 15: 1427-1430, 1988.
PubMed
15) De Keyser F, Verbruggens G, Veys EM, et al: Tcell receptor V usage in rheumatoid nodules: marked oligoclonality amaong IL 2-expanded lymphocytes. Clin Immunol Immunopahtol 68: 29-34, 1993.
 
16) van Zeben D, Hazes JMW, Zwinderma AH, et al: Association of HLA-DR 4 with a more progressive disease course in patients with rheumatoid arthritis. Arthritis Rheum 34: 822-830, 1991.
 
17) Weyand MC, Hicok KC, Conn DL, et al: The influence of HLA-DRB genes on disease severity in rheumatoid arthritis. Ann Intern Med 117: 801-806, 1992.
 
18) Abu-Shakra M, Nicol P, Urowitz MB: Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy. J Rheumatol 21: 934-937, 1994.
PubMed
19) Segal R, Caspi D, Tishler M, et al: Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 31: 1182-1185, 1988.
PubMed
P.25 掲載の参考文献
1) Mizuki N, Inoko H, Kashiwase K, et al: Behcet's disease associated with one of the HLA-B51 subantigens, HLA-B*5101. Am J Ophthalmol 116: 406-409, 1993.
PubMed
2) 水島裕, 松田隆秀: 多施設による菌体抽出成分をもちいた皮膚テスト. 厚生省特定疾患ベーチェット病調査研究班昭和62年度研究業績, pp17-30, 1988.
 
3) 山下直美: ベーチェット病の免疫異常とその制御. 厚生省特定疾患ベーチェット病調査研究班平成6年度研究業績, pp54-55, 1995.
 
4) 笹田昌孝, 浅越康助, 芝田榮里ら: ベーチェット病の病態形成における血小板と好中球の相互作用の意義. 厚生省特定疾患ベーチェット病調査研究班 平成5年度研究業績, pp129-131, 1993.
 
5) 笹田昌孝, 浅越康助, 高橋淳ら: ベーチェット病患者単球の機能異常に関する検討厚生省特定疾患ベーチェット調査研究班 平成4年度研究業績, pp119-121, 1993.
 
6) 中江公裕, 橋本喬史, 稲葉午朗ら: ベーチェット病患者全国疫学調査成績 (第1報). 厚生省特定疾患ベーチェット病調査研究班 平成4年度研究業績, pp63-69, 1993.
 
7) 東田みち代, 中川やよい, 多田玲ら: 1990 (平成2) 年におけるベーチェット病の現況. 日本眼科紀要42: 1014-1018, 1990.
 
8) 中江公裕, 橋本喬史, 稲葉午朗ほか: ベーチェット病患者全国疫学調査成績 (第2報). 厚生省特定疾患べーチェット病調査研究班 平成4年度研究業績, pp70-82, 1993.
 
9) 三村康男: アレルギー性眼疾患の病態と治療. 日眼会誌83: 1909-1975, 1979.
 
10) Nussenblat RB, Palestine AG: Cyclosporine-Immunology, pharmacology and therapeutic uses. Surv Ophtalmol 31: 159-169, 1986.
 
11) 湯浅武之助, 永江康信, 原吉幸ら: ベーチェット病の眼病変に対するステロイドの長期持続投与法. 厚生省特定疾患ベーチェット病調査研究班 平成6年度研究業績, pp165-167, 1995.
 
P.31 掲載の参考文献
1) Friedreich N, Kekule A: Zur Amyloidfrage. Virchows Arch[A] 16: 50, 1859
 
2) Foerster J: Amyloidosis. In: Wintrobe's Clinical Hematology g th Ed (Ed, Lee GR, et al), pp. 2271-2283, Lea &Febiger, 1993
 
3) 七川歡次: アミロイドーシスとリウマチ病. リウマチ24: 190-197, 1984
 
4) Kyle RA, Greipp PR, Garton JP, et al: Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 79: 708-710, 1985
PubMed
5) Skinner M, Anderson J, Simms R, et al: Randomized trial of treatment for primary (AL) amyloidosis. Arthritis Rheum 37 (suppL 9): S427, 1994 (abstract)
 
6) 中澤了一: 全身性アミロイドーシスに見られる臓器障害-症候論と診断法-. 骨, 関節. 日本臨牀49: 138-143, 1991
 
7) 中井秀紀, 尾崎承一, 狩野庄吾ら: 多施設研究による本邦の慢性関節リウマに合併する続発性アミロイドーシスの臨床的特徴と遺伝的背景. リウマチ36: 25-33, 1996
 
8) Baba S, Sonomi AM, Takahashi T, et al: A novel allellic variant of serum amyloid A, SAA 1γ genomic evidence, evolution, frequency, and implication as a ris factor for reactive systemic AA-amyloidosis. Human Molecular Genetics 4: 1083-1087, 1995
 
9) Friedman R, Agus B, Ames E: Amyloid arthropathy in patient with psoriasis and amyloidosis. Arthritis Rheum 24: 1320-1323, 1981
PubMed
10) 前田憲志, 宮田敏男, 新里高弘: 透析アミロイドーシスについて. 綜合臨牀45: 1383-2386, 1996
 
11) Ladefoged Chr: Amyloid depositions in the knee joint at antopsy. Ann Rheum Dis 45: 668-672, 1986
 
12) Ladefoged Chr, Fedders O, Petersen OF: Amyloid in intervertebral disc: a histopathological investigation of surgical material from 100 constectutive operations on herniated discs. Ann Rheum Dis 45: 239-243, 1986
 
P.43 掲載の参考文献
1) Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982
PubMed
2) Petri M, Genovese M, Engle E, et al: Definition, incidence, and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum 34: 937-944, 1991
PubMed
3) Bombardier C, Gladman DD, Urowitz MB, et al: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35: 630-640, 1992
PubMed
4) Liang MH, Socher SA, Larson MG, et al: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32: 1107-1118, 1989
PubMed
5) Symmons DPM, Coppock JS, Bacon PA, et al: Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Quarterly J Med 258: 927-937, 1988
 
6) Gladman DD, Goldsmith CH, Urowitz MB, et al: Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 21: 1468-1471, 1994
 
7) Corzillius M, Schroeder JO, Euler HH: Comparison of different activity scores, laboratory parameters and treatment decisions in 50 patients with SLE, p126, Proceedings of the European Lupus Conference, November, 1990
 
8) 横張龍一: SLE活動性判定基準. 厚生省特定疾患自己免疫疾患調査研究班 (班長恒松徳五郎) 昭和60年度研究業績, p. 50, 1986
 
9) 橋本博史, 広瀬俊一, 狩野庄吾ら: 全身性エリテマトーデスの病型分類に関する全国調査結果について-各種臨床病態別による転帰と治療法の解析-. リウマチ32: 27-38, 1992
 
10) Abu-Shakra M, Urowitz MB, Gladman DD, et al: Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22: 1265-1270, 1995
PubMed
11) ter Borg EJ, Horst G, Hummell EJ, et al: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus, a long term, prospective study. Arthritis Rheum 33: 634-643, 1990
 
12) Bootsma H, Spronk P, Derksen R, et al: Prevention of relapses in systemic lupus erythematosus. Lancet 345: 1595-1599, 1995
PubMed
13) Spronk PE, Bootsma H, Huitema MG, et al: Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 197: 439-444, 1994
 
14) Janssen BA, Luqmani RA, Gordon C, et al: Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 33: 1112-1116, 1994
PubMed
15) Belmont HM, Buyon J, Giorno R, et al: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37: 376-383, 1994
PubMed
16) Milis L, Timmermans V, Morris CA, et al: The value of complement measurements in the assessment of lupus activity. Aust NZ J Med 22: 338-344, 1992
 
17) Porcel JM, Ordi J, Castro-Salomo A, et al: The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 74: 283-288, 1995
PubMed
18) Marquart HV, Svendsen A, Rasmussen JM, et al: Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus. Clin Exp Immunol 101: 60-65, 1995
 
19) Spronk PE, ter Borg EJ, Huitema MG, et al.: Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 53: 235-239, 1994
PubMed
20) Neish C, Charley M, Fertig N, et al: Elevated serum soluble interleukin-2receptor levels in subacute cutaneous lupus erythematosus, J Dermatol Sci 5: 143-149, 1993
 
21) Linker-Israeli M, Hyun S, Ozeri-Chen T, et al: Elevated in vivo and in vitro secretion of CD 8-α molecules in patients with systemic lupus erythematosus. J Immunol 152: 3158-3167, 1994
 
22) Nocker WA, Wigand R, Schoeppe W, et al: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 96: 15-19, 1994
 
23) Hsieh SC, Tsai CY, Sun KH, et al: Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol 34: 107-112, 1995
PubMed
24) 斉藤元章, 植地泰之, 中林公正ら: BacteriophageλDNAを抗原とした抗二本鎖および抗一本鎖DNA抗体の測定-ループス腎炎患者における抗DNA抗体とその親和性の検討-. 日腎会誌36: 1103-1112, 1994
 
25) Siegert CEH, Daha MR, Tseng CMES, et al: Predictive value of IgG autoantibodies against C 1 q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52: 851-856, 1993
 
26) Elkayam O, Tamir R, Pick AI, et al: Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus. Allergy 50: 94-96, 1995
PubMed
27) Atta MS, Lim KL, Alap 4 deen DA, et al: Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann Rheum Dis 54: 117-124, 1995
 
28) Pauzner R, Urowitz M, Gladman D, et al: Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol 21: 1670-1673, 1994
PubMed
29) Saxena R, Sturfelt G, Nived O, et al: Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders. Ann Rheum Dis 53: 659-665, 1994
PubMed
30) Boehme MWJ, Nawroth PP, Kling E, et al: Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 37: 572-577, 1994
 
31) Ohdama S, Yoshizawa Y, Kubota T, et al,: Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus. Int J Cardiol 47: S1-S6, 1994
PubMed
32) Lim KL, Muir K, Powell RJ: Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 53: 743-748, 1994
PubMed
33) Kammer GM, Khan IU, Malemud CJ: Deficient type 1 protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 94: 422-430, 1994
PubMed
34) Lacki JK, Schochat T, Leszczynski P, et al: IgA-alpha-1-antitrypsin complex in systemic lupus e rythematosus: preliminary report. Lupus 4: 221-224, 1995
 
35) Pruzanski W, Goulding NJ, Flower RJ, et al: Circulating groupIIphospholip-ase A 2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol 21: 252-257, 1994
 
36) Esdaile JM, Abrahamowicz M, Joseph L, et al: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Arthritis Rheum 39: 370-378, 1996
PubMed
37) Walz LeBlanc BAE, Gladman DD, Urowitz MB: Serologically active clinically quiescent systemic lupus erythematosus-Predictors of clinical flares. J Rheumatol 21: 2239-2241, 1994
 
P.51 掲載の参考文献
1) Wolfe F, Hawley DJ: Remission in Rheumatoid Arthritis. J Rheumatol 12: 245-252, 1985
PubMed
2) Pemberton R, Pierce EC: Clinical and stastical study of chronic arthritis based on 1100 cases. Am JMed Sci 173: 31-36, 1927
 
3) Thompson HE, Wyatt BL, Hicks RA: Chronic atrophic arthritis. Ann Intern Med 11: 1792-1805, 1938
 
4) Ragan C: The general management of rheumatoid arthritis. JAMA 141: 125-127, 1949
 
5) Corrigan AB, Robinson RG, Terenty TR, et al: Benign rheumatoid arthritis of the aged. Brit Med J 1: 444-446, 1974
PubMed
6) Srinivasan R, Miller BL, Paulus HE: Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum 22: 105-110, 1979
PubMed
7) Sambrook PN, Browne CD, Champion GD, et al: Terminations of treatment with gold sodium thiomalate in rheumatoid arthrit is, J Rheumatol 9: 932-934, 1982
 
8) Anderson JJ, Felson DT, Meenan RF, et al: Which Traditional measures should be used in rheumatoid arthritis clinical trials?Arthritis Rheum 32: 1093-1099, 1989
PubMed
9) Bombardier C, Raboud J, et al: A comparison of health-related quality-of-life measures for rheumatoid arthritis research. Controlled Clin Trials 12: 243 S-256S, 1991
 
10) Gotzsche PC: Sensitivity of effect variables in rheumatoid arthritis: ameta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 43: 1313-1318, 1990
 
11) Felson DT, Anderson JJ, Boers M, et al: The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheumatol 36: 729-740, 1993
 
12) Tugwell P, Boers M: OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 20: 528-530, 1993
PubMed
13) Pinals RS, Masi AT, Larsen RI, et al: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheumatol 10: 1308-1315, 1981
 
14) Alarcon GS, Blackburn WD Jr, Calvo A, et al: Evaluation of the American Rheumatism association preliminary criteria for remission in rheumatoid arthritis: A prospective study. J Rheumatol 14: 93-96, 1987
PubMed
15) 安倍達, 竹内勤, 伊藤功ら: 慢性関節リウマチの寛解基準. リウマチ科14: 135-139, 1995
 
16) Scott DL, Dawes PT, Fowler PD, et al: Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med 54: 49-59, 1985
PubMed
17) Mottonen TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 47: 648-653, 1988
PubMed
18) Fuchs HA, Callahan LF, Kaye JJ, et al: Radiographic joint count findings of the hand in rheumatoid arthritis: related and unrelated findings. Arthritis Rheumatism 31: 44-51, 1988
PubMed
19) Pincus T, Callahan LF, Brooks RH, et al: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 110: 259-266, 1989
PubMed
20) Van der Heijde DMFM, van't Hof MA, van Riel PLCM, et al: A comparison of validity of single variables and composed indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51: 177-181, 1992
 
P.58 掲載の参考文献
1) Carter RL: Livedo. In: Dictionary of Dermatologic Terms, 4th Ed. p. 220, Baltimore, Williams& Wilkins, 1992
 
2) 川津智是: 網状皮斑. 現代皮膚科学大系17 (山村雄一, 久木田淳, 佐野榮春ら編), pp. 122-125, 東京, 中山書店, 1983
 
3) Champion RH: Reactions to cold. In Textbook of Dermatology, 5th Ed (Ed, Champion RH, Burton JL, Ebling FJG) p. 837, Oxford, Blackwell, 1992
 
4) Dover JS, Dowd PM, Tonnesen MG: Cutaneous effects of heat and cold. In: Cutaneous Medicine and Surgery, An Integrated Program in Dermatology (Ed, Arndt KA, LeBoit PE, Robinson JK, et al) pp. 831-832, Philadelphia, WB Saunders, 1996
 
5) O'Leary PA, Montgomery H, Brunsting LA: Livedo reticularis;recurring ulcerations of the ankles in the summer. Arch Dermatol & Syph 50: 213, 1944
 
6) O'Leary PA, Montgomery H, Brnsting LA, et al: Summer ulcerations with livedo reticularis. Arch Dermatol 71: 279, 1955
 
7) Feldaker M, Hines EA, Kierland RR: Livedo reticularis with summer ulcerations. Arch Dermatol 72: 31-42, 1955
 
8) Bard JW, Winkelmann RK: Livedo vasculitis: segmental hyalinizing vasculitis of the dermis. Arch Dermato196: 489-499, 1967
PubMed
9) Winkelmann RK, Schroeter AL, Kierland RR, et al: Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis). Mayo Clin Proc 49: 746-750, 1974
PubMed
10) McCalmont TH, Pennella R: Noninflammatory small vessel occlusive diseases. In: Cutaneous Medicine and Surgery, An Integrated Program in Dermatology (Ed, Arndt KA, LeBoit PE, Robinson JK, et al) pp. 543-546, Philadelphia, WB Saunders, 1996
 
11) Shornick JK, Nicholes BK, Bergstressor PR, et al: Idiopathic atrophie blanche. J Am Acad Dermatol 8: 792-798, 1983
 
12) 足立厚子, 石田としこ, 中村麻紀ら: Livedoid vasculitis. 臨床皮膚科44: 177-183, 1990
 
13) McCalmont CS, McCalmont TH, Jorizzo, JL, et al: Livedo vasculitis: vasculitis or thrombotic vasculopathy?Clin Exp Dermatol 17: 4-8, 1992
 
14) Sneddon IB: Cerebrovascular lesions and livedo reticularis. Br J Dermatol 77: 180-185, 1965
PubMed
15) Daoud MS, Wilmoth GJ, Su WPD, et al: Sneddon syndrome. Semin Dermatol 14: 166-172, 1995
 
16) Zelger B, Sepp N, Schmid KW, et al: Life history of cutaneous vascular lesions in Sneddon's syndrome. Hum Pathol 23: 668-675, 1992
PubMed
17) Zelger B, Sepp N, Stockhammer G, et al: Sneddon: s syndrome. Arch Dermatol 129: 437-447, 1993
PubMed
18) Piette JC, Frances C: The mystery of antiphospholipid antibodies in Sneddon's syndrome. Arch Dermatol 130: 519-520, 1994
PubMed
19) Frances C, Tonqueze L, Salohzin KV, et al: Prevalence of anti-endothelial cell antibodies in patients with Sneddon's syndrome. J Am Acad Dermatol 33: 64-68, 1995
 
20) Klein KL, Pittelkow MR: Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 67: 923-933, 1992
PubMed
21) Murrell DF, Jensen J, Hill C, et al: Failure of livedoid vasculitis to respond to tissue plasminogen activator. Arch Dermatol 131: 231-232, 1995
 
22) Johnson DW, Hawley CM, Strutton G, et al: Dramatic response of livedoid vasculitis to tissue plasminogen. Aust N Z J Med 25: 370-371, 1995
PubMed

骨関節,脊椎,神経

P.69 掲載の参考文献
1) Altman R, Asch E, Bloch D, et al: Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 29: 1039-1049, 1986
PubMed
2) 吉野良平: 骨関節症のリスクファクター. リウマチ病セミナーI (七川歡次監修), pp. 157-170, 大阪, 永井書店, 1990
 
3) Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimates of the prevalence of selected arthritis and musclocutaneous diseases in the United States. J Rheumatol 16: 427-441, 1989
 
4) Van Sasse JLCM, Van Romunde LKI, Cats A, et al: Epidemiology of osteoarthritis: Zoertermeer survey. Comparison of radiologic osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 48: 271-280, 1989
 
5) Cecil RL, Archer BH: Classification and treatment of chronic arthritis. JAMA 87: 741-746, 1926
 
6) Kellgren JH, Moore R: Generalised osteoarthritis and Heberden's nodes. Br Med J 1: 181-187, 1952
 
7) Spector TD, Brown GC, Silman AJ: Increased rates of prior hysterectomy and gynaecological operations in women with osteoarthritis. Br Med J 297: 899-900, 1988
 
8) Hannan MT, Felson DT, Anderson JJ, et al: Estrogen use and radiographic osteoarthritis of the knee in women. Arthritis Rheum 33: 525-532, 1990
PubMed
9) Inoue K, Ushiyama T, Kim Y, et al: Inceased rate of hysterectomy in women undergoing surgery for osteoarthritis of the knee. Osteoarthritis Cart 3: 205-209, 1995
 
10) Spector TD, Perry LA, Jubb RW: Endogenous sex steroid levels in women with generalised osteoarthritis. Clin Rheumatol 10: 316-319, 1991
PubMed
11) Eriksen EF, Colvard DS, Berg NJ, et al: Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84-86, 1988
PubMed
12) Komm BS, Terpening CM, Benz DJ, et al: Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241: 81-84, 1988
PubMed
13) Young PCM, Stack MT: Estrogen and glucocorticoid receptors in adult canine articular cartilage. Arthritis Rheum 25: 568-573, 1982
 
14) Ushiyama T, Inoue K, Nishioka J: Expression of estrogen receptor related protein (p29) and estradiol binding in human arthritic synovium. J Rheumatol 22: 421-426, 1995
PubMed
15) Rosner IA, Goldberg VM, Getzy L, et al: Effects of estrogen on cartilage and experimentally induced osteoarthritis. Arthritis Rheum 22: 52-58, 1979
PubMed
16) Rosner IA, Malemund CJ, Goldberg VM, et al: Pathologic and metabolic responses of experimental osteoarthritis to estradiol and an estradiol antagonist. Clin Orthop 171: 280-286, 1982
 
17) Herbai G: Autoradiographic studies with 35S-Sulfate on somatotrophin and estrogen sensitivite growth zones in rat and mouse costal cartilage. Acta Physiol Scand 79: 351-358, 1970
PubMed
18) Priest RE, Koplitz RM, Benditt EP: Estradiol reduces incorporation of radioactive sulfate into cartilage and aortas of rats. J Exp Med 112: 225-236, 1960
PubMed
19) Mackintosh D, Mason RM: Pharmacological actions of oestradiol 17 beta on articular cartilage chondrocytes and chondrosarcoma chondrocytes. Biochem Biophys Acta 59: 246-248, 1988
 
20) Scranton PE, Mcmaster JH, Diamond PE: Hormone suppression of DNA synthesis in cultured chondrocyte and osteosarcoma cell lines. Clin Orthop 112: 340-348, 1975
PubMed
21) Guerne PA, Carson DA, Lotz M: IL-6 production by human chondrocytes: modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 144: 499-505, 1990
PubMed
22) Silberberg M, Silberberg R: Modifying action of estrogen on the evolution of osteoarthritis in mice of different ages. J Endocrinol 72: 449-451, 1963
 
23) Rosner IA, Goldberg VM, Moskowitz RW: Estrogen and osteoarthritis, Clin Orthop 213: 77-83, 1986
PubMed
24) Tsai C-L, Liu T-K: Estradiol-induced knee osteoarthrosis in ovariectomized rabbits. Clin Orthop 291: 295-302, 1993
PubMed
25) Hartz AJ, Fischer ME, Bril G, et al: The association of obesity with joint pain and osteoarthritis in the HANES data. J Chron Dis 39: 311-319, 1986
 
26) Felson DT, Anderson JJ, Naimark A, et al: 0besity and knee osteoarthritis. Ann Int Med July 1: 18-24, 1988
 
27) Felson DT, Anderson JJ, Naimark A, et al: Does smoking protect against knee osteoarthritis (OA)?Arthritis Rheum 31: B39, 1988
 
28) Verstraeten A, Van Ermen H, Haghebaert G, et al: Osteoarthrosis retards the development of osteoporosis. Clin Orthop 264: 169-177, 1991
PubMed
P.76 掲載の参考文献
1) 木村友厚: コラーゲンのtypingと分布. リウマチ病セミナーII (七川歡次監修), pp. 167-172, 大阪, 永井書店, 1991
 
2) 安井夏夫: 骨形成不全症の分類. リウマチ病セミナーI (七川歡次監修), pp. 171-181, 大阪, 永井書店, 1990
 
3) Tsipouras P: Osteogenesis imperfecta. In: McKusick's Heritable Disorders of Connective Tissue (Ed, Beighton P), pp. 281-314, St. Louis, Mosby, 1993
 
4) Prockop DJ, Kivirikko KI: Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem 64: 403-434, 1995
PubMed
5) 木村友厚, 妻木範行, 松井好人: 骨軟骨基質蛋白の異常と骨軟骨疾患. 実験医学14: 1468-1474, 1996
 
6) Vikkula M, Metsaranta M, Ala-Kokko L: Type II collagen mutations in rare and commom cartilage diseases. Ann Med 26: 107-114, 1994
 
7) 木村友厚, 妻木範行, 松井好人: 分子生物学的に解明されたコラーゲン分子と病態的意義. リウマチ35: 600-608, 1995
 
8) Pun YL, Moskowitz RW, Lie S, et al: Clinical correlations of osteoarthritis associated with a single-base mutation (arginine 519 to cysteine) in type II procollagen gene. Arthritis Rheum 37: 264-269, 1994
 
9) Jacenko O, LuValle PA, Olsen BR: Spondylometaphyseal dysplasia in mice carrying a dominant negative mutation in a matrix protein specific for cartilage-to-bone transition. Nature 365: 56-61, 1993
 
10) Nakata K, Ono K, Miyazaki J, et al: Osteoarthritis associated with mild chondrodysplasia in transgenic mice expressing α1 (XI) collagen chains with a central deletion. Proc Natl Acad Sci USA 90: 2870-2874, 1993
 
11) Kimura T, Nakata K, Tsumaki N, et al: Altered chondrocyte gene expression in articular cartilage matrix components and susceptibility to cartilage destruction. In: Cell Mechanics and Cellular Engineering (Ed, Mow VC, et al), pp445-456, New York, Springer. Verlag, 1994
 
12) Warman ML, Abbott M, Apte SS, et al: A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. Nature Genet 5: 79-82, 1993
PubMed
13) Muragaki Y, Mariman ECM, van Beersum SEC, et al: A mutation in the gene encoding theα2 chain of the fibril-associated collagen IX, COL g A 2, causes multiple epiphyseal dysplasia (EDM 2), Nature Genet 12: 103-105, 1996
 
14) Vikkula M, Mariman ECM, Lui VCH, et al: Autosomal dominant and recessive osteochondrodys-plasias associated with the COL11A 2 loculs. Cell 80: 431-437, 1995
 
15) Hecht JT, Nelson LD, Crowder E, et al: Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nature Genet 10: 325-329, 1995
PubMed
16) Briggs MD, Hoffman SMG, King LM, et al: Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nature Genet 10: 330-336, 1995
 
17) Thomas JT, Lin K, Nandedkar M, et al: Ahuman chondrodysplasia due to a mutation in a TGF-βsuperfamily member. Nature Genet 12: 315-317, 1996
 
18) Rousseau F, Bonaventure J, Legeai-Mallet L, et al: Mutations in the gene encoding fibroblast growth factor receptor-3in achondroplasia. Nature 371: 252-254, 1994
 
19) Shiang R, Thompson LM, Zhu Y-Z, et al: Mutations in the transmembrane domain of FGFR 3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78: 335-342, 1994
 
20) Matsui Y, Kimura T, Tsumaki N, et al: A commom FGFR 3 mutation functions as a diagnostic marker for achondroplasia-group disorders in the Japanese population. J Orthop Sci 1: 130-135, 1996
 
21) Schipani E, Kruse K, Juppner H: A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268: 98-100, 1995
PubMed
22) Muragaki Y, Mundlos S, Upton J, et al: Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 272: 548-551, 1996
PubMed
P.85 掲載の参考文献
1) Dam H: Antihaemorragic vitamin of chick. Biochem J 29: 1273-1285, 1935
 
2) Doisy EA, MacCorquodale DW, Thayer SA, et al: The isolation, constitution, and synthesis of vitamin K1. Science 90: 407, 1939
 
3) 日本ビタミン学会: ビタミンK. ビタミンハンドブック (1) 脂溶性ビタミン (池田ら編集), pp. 73-87, 京都, 化学同人, 1989
 
4) Bouckaert JH, Said AH: Fracture healing by vitamin K. Nature 185: 849, 1960
PubMed
5) Stenflo J, Fernlund P, Egan W, et al: Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci 71: 2730-2733, 1974
PubMed
6) Gallop PM, Lian JB, Hauschka PV: Carboxyl ated calcium-binding proteins and vitamin K. New Engl J Med 302: 1460-1466, 1980
 
7) Hauschka PV, Lian JB, Gallop PM: Direct identification of the calcium-binding a mino acid, γ-carboxyglutamate, in mineralized tissue. Proc Nat. Acad Sci USA 72: 3925-3929, 1975
 
8) Nishimoto SK, Price PA: Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells;evidence for an intracellular precursor. J biol Chem 255: 6579-6583, 1980
PubMed
9) 上好昭孝: オステオカルシン. 臨床検査34: 1558-1562, 1990
 
10) Plantalech L, Guillaumont M, Vergnaud P, et al: Impairment of gamma carboxylation of circulating osteocalcin (Bone Gla Protein) in elderly women. J Bone Miner Res 6: 1211-1216, 1991
PubMed
11) Koshihara Y, Kawamura M, Endo S, et al: Establishment of human osteoblastic cells derived from periosteum in culture. In vitro Cell Dev Biol 25: 37-43, 1989
PubMed
12) Hara K, Akiyama Y, Tajima T, et al: Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J Bone Miner Res 8: 535-542, 1993
PubMed
13) Akiyama Y, Hara K, Ohkawa I, et al: Effects of menaterenone on bone loss inducd by ovarectomy in rats. Japan J Pharmacol 62: 145-153, 1993
 
14) Hara K, Akiyama Y, Ohkawa I, et al: Effects of menatetrenone on predonisolone-induced bone loss in rats. Bone 14: 813-818, 1993
 
15) Hart JP, Shearer MJ, Klenerman L, et al: Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endrocrinol Metab 60: 1268-1269, 1985
 
16) Bitensky L, Hart JP, Catterall A, et al: Circulating vitamin K levels in patients with fractures. J Bone Joint Surg 70-B: 663-664, 1988
 
17) Hodges SJ, Pilington MJ, Stamp TCB, et al: Depressed levels circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 12: 387-389, 1991
 
18) Knapen MHJ, Hamulya: k K, Vermeer C: The effect of vitamin K supplementation on circulating osteocalcin (bone gla protein) and urinary calcium excretion. Ann Inter Med 111: 1001-1005, 1989
 
19) 秋口格, 白木正孝, 井藤英喜ら: 閉経後骨粗鬆症に対するビタミンK2の骨塩増加作用. 日内分泌会誌59: 404, 1983
 
20) Price PA, Otsuka AS, Poser JW, et al: Characterization of a γ-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 73: 1447-1451, 1976
 
21) 森井浩世, 三木隆己: オステオカルシン研究. 腎と骨代謝1: 9-24, 1988
 
P.97 掲載の参考文献
1) 西林保朗: 股関節周辺のbursitis. リウマチ病セミナーI (七川歡次監修), pp. 108-156, 永井書店, 大阪, 1990
 
2) 鳥巣岳彦: 股関節周囲でみられる滑液包の疾患. 新図説臨床整形外科講座7 (松崎昭夫編集), pp. 223-224, 東京, メジカルビュー社, 1994
 
3) 富田勝郎, 仲克己: 骨.関節結核の診断と治療のポイント. 別冊整形外科15: 222-225, 1989
 
4) 山本三希雄, 今井望, 有馬享ら: 骨関節結核-保存的治療症例の経過-. 別冊整形外科15: 235, 1989
 
5) 増田祥男: 股関節周囲の骨. 軟部悪性腫瘍. 癌の外科15: 手術手技シリーズ5 骨・軟部悪性腫瘍, pp. 52-69, 東京, メジカルビュー社, 1992
 
6) 鳥山貞宜, 大幸俊三, 川野寿ら: 骨盤部悪性腫瘍の治療. 日整会誌61: 1343-1356, 1987
 
7) 井村慎一, 松永隆信: 股関節診療ハンドブック, 弾発股, pp. 237-240, 東京, 南江堂, 1990
 
8) 森永伊昭: 弾発股の12例, その原因および治療法についての考察. 整形外科39: 351-357, 1988
 
9) 西林保朗: Piriformis Syndrome. リウマチ病セミナー II (七川歡次監修), pp. 117-136, 大阪, 永井書店, 1991
 
10) 島田永和: 梨状筋症候群-梨状筋切除術-. 臨床スポーツ医学9: 43-45, 1992
 
11) 本郷一郎: 結合組織炎症候群. リウマチ病セミナーI (七川歡次監修), pp. 95-111, 大阪, 永井書店, 1990
 
12) Muhammad BY: Fibromyalgia syndrome and myofascial pain syndrome. In: Myofascial pain and fibromyalgia (Ed, Rachlin ES). pp. 3-29, St. Louis, Mosby, 1994
 
13) 井村慎一: 変形性股関節症. 新図説臨床整形外科講座7 (松崎昭夫編集). pp. 156-174, 東京, メジカルビュー社, 1994
 
14) 久保俊一, 井上重洋: 整形外科special発育期における股関節のスポーツ障害・外傷 (山本龍二編集). pp. 90-100, 東京, メジカルビュー社, 1994
 
15) Maigne R, Maigne JY: Syndrome des branches perforantes laterales des nerfs sous-costal et iliohypogastrique. Une cause mecanique de douleurs de hanche. Rev Rhum 53: 307-311, 1986
 
P.105 掲載の参考文献
1) Imai S, Hukuda S, Maeda T: Dually innervating nociceptive networks in the rat lumbar posterior longitudinal ligaments. Spine 20: 2086-2092, 1995
PubMed
2) 李芳祥, 福田眞輔, 今井晋二ら: ラット腰椎後縦靭帯における侵害受容神経と交感神経の関わり. Calcitonin gene-related peptide と tyrosine hydroxylaseの免疫組織化学と免疫電顕による考察. 日関外誌15: 187-202, 1996
 
3) 小林茂, 吉沢英造, 中井定明ら: 腰椎椎間板ヘルニアの自然縮小機序・病理組織像および電顕像による観察. 整災外39: 3-14, 1996
 
4) 小宮靖弘: ヒト関節滑膜におけるtissue inhibitor of metalloproteases (TIMP) およびstromelysinの免疫組織化学的局在. 日関外誌11: 59-70, 1992
 
5) Kanemoto M, Hukuda S, Komiya Y, et al: Immunohistochemical study of matrix metalloprotein ase-3 (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in human intervertebral disc. Spine 21: 1-8, 1996
 
6) 東城博雅: ホスホリパーゼA2と炎症. リウマチ病セミナーV (七川歡次監修), pp193-202, 大阪, 永井書店, 1994
 
7) Saal JS, Franson RC, Dobrow R, et al: High levels of inflammatory phospholipase A2 activity in lumbar disc herniations. Spine 15: 674-678, 1990
PubMed
8) Miyahara K, Ishida T, Hukuda S, et al: Human group II phospholipase A2 in normal and diseased intervertebral discs. Submitted to Biochimica et Biophysica Acta (in press).
 
P.111 掲載の参考文献
1) Kaplan FS, August CS, Sallon MD, et al: Successful treatment of infantile malignant osteopetrosis by bone-marrow transplantation. J Bone Joint Surg 70-A: 617-623, 1988.
 
2) Dorantes LM, Mejia AM, Dorantes S: Juvenile osteopetrosis: Effects on blood and bone of prednisone and a low calcium, high phosphate diet. Arch Dis Child 61: 666-670, 1986
 
3) Blazar BR, Fallon MD, Teitelbaum SL, et al: Calcitriol for congenital osteopetrosis. N Eng J Med 311: 55, 1984
 
4) Horton WA, Schimke RN, Iyama T: Osteopetrosis: Further heterogeneity. J Pediat 97: 580-585, 1980
PubMed
5) Kaibara N, Katsuki I, Hotokebuchi T, et al: Intermediate form of osteopetrosis with recessive inheritance. Skeletal Radiol 9: 47-51, 1982
PubMed
6) 水島哲也: 大理石骨病の診断と治療MB Orthop 6: 87-91, 1993
 
7) 吉田尚弘, 林真一, 西川伸一: M-CSFの変異と大理石病 (骨化石症). 代謝 29 増刊: 145-152, 1992
 
8) Johnson RS,Spiegelman BM,Papaioannou V:Pleiotropic effect of a null mutation in the c-fos proto-oncogene.Cell 71: 577-586, 1992
 
9) Kodama H, Yamasaki A, Nose M, et al: Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Ecp Med 173: 269-272, 1991
 
10) 元吉和夫: M-CSFの臨床応用. 臨床医19: 1978-1982, 1993
 
11) Grigoriadis AE, Wang zQ, Cecchini MG, et al: c-fos: Akey regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448, 1994
 
12) 小玉博明, 新飯田俊平: M-CSFによる大理石骨病の治療. 日常診療と血液2: 1197-1203, 1992
 
P.127 掲載の参考文献
1) Caplan A: Certain unusual radiological appearances in the chests of coal-miners suffering from rheumatoid arthritis. Thorax 8: 29-37, 1953
PubMed
2) 松岡芳子, 富田真佐子, 吉野泉ら: じん肺と自己免疫疾患. 産業医学34: 421-431, 1992
 
3) 田中善紹, 後藤武近, 藤田幸久ら: じん肺に合併した自己免疫疾患の臨床的検討. 日胸52: 849-853, 1993
 
4) Sanchez-Roman J, Wichmann I, Salaberri J, et al: Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 52: 534-538, 1993
PubMed
5) 田村猛夏, 董良, 徳山猛ら: 石綿工場従業員における自己抗体の出現と胸部X線所見との関連. 産業医学35: 406-412, 1993
 
6) 得丸幸夫, 平山惠造, 北耕平ら: 珪肺症に合併した感覚性運動失調型ニューロパチーの2症例. 臨床神経学 30: 933-938, 1990
 
7) Silman AJ, Hochberg MC: Epidemiology of the rheumatic diseases. Oxford, Oxford University Press, 1993
 
8) 村田紀和, 梅木健一: Sjogren症候群と骨関節症状. リウマチ病セミナーVI (七川歡次監修), pp. 51-57, 大阪, 永井書店, 1995
 
9) Resnick D, Niwayama G: Osteolysis and chondrolysis. In: Diagnosis of bone and joint disorders (Ed, Resnick D), pp. 4467-4489, Philadelphia, Saunders, 1995
 
10) Lundberg I, Alfredsson L, Plato N, et al: Occupation, occupational exposure to chemicals and rheumatological disease. Scand J Rheumatol 23: 305-310, 1994
PubMed
11) Rosenman KD, Zhu ZW: Pneumoconiosis and associated medical conditions. Am J Ind Med 27: 107-113, 1995
 
12) Batuman V: Lead nephropathy, gout, and hypertension. Am J Med Sci 305: 241-247, 1993
PubMed
13) Lawrence JS: Occupational aspects of the rheumatic diseases. In: Rheumatism in populations, pp. 466-493, London, Williams Heinemann, 1977
 
14) Vingard E, Alfredsson L, Goldie I, et al: Occupation and osteoarthrosis of the hip and knee: A resister-based cohort study. Internat J Epidemiol 20: 1025-1031, 1991
 
15) Nakamura R, Ono Y, Horii E, et al: The etiological significance of work-load in the development of osteoarthritis of the distal interphalangeal joint. J Hand Surg 18B: 540-542, 1993
 
16) Stenlund B, Goldie I, Hagberg M, et al: Radiographic osteoarthrosis in the acromioclavicular joint resulting from manual work or exposure to vibraiton. Br J Ind Med 49: 588-593, 1992
PubMed
17) Videman T, Nurminen M, Troup JDG: Lumbar spinal pathology in cadaveric material in relation to history of back pain, occupation and physical loading. Spine 15: 728-740, 1990
 
18) Toroptsova NV, Benevolenskaya LI, Karyakin AN, et al: "Cross-sectional"study of low back pain among workers at an industrial enterprise in Russia. Spine 20: -328-332, 1995
PubMed
19) Spitzer WO (Chairman): Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Spine 12 (7S), Europian eddition suppl 1, 1987
 
20) Kahn MF, M: Bappe P, Rouaud JP: Pathologie de surmenage professionnel. In L'Actualite Rhumatologique 1994 (Ed, de Seze S, Ryckewaert A, Kahn MF, et al), pp. 78-85, Paris, L: Expansion Scientifique, 1994
 
21) Sheon RP, Moskowitz RW, Goldberg VM: Soft tissue rheumatic pain. Recognition, management, and prevention, 3rd ed, Baltimore, Williams &Wilkins, 1996
 
22) Becker W, Krahl H: Die Tendopathien. Stuttgart, Thieme, 1978
 
23) 西林保朗: 股関節周辺のbursitis. リウマチ病セミナーI (七川歡次監修), pp. 136-156, 大阪, 永井書店, 1990
 
24) Dawson DM, Hallett M, Millender LH: Entrapment Neuropathies. Boston, Little, Brown, 1983
 
25) 西林保朗: Piriformis Syndrome. リウマチ病セミナーII (七川歡次監修), pp. 117-136, 大阪, 永井書店, 1991
 
26) Sanders RJ: Thoracic outlet syndrome. A common sequela of neck injuries. Philadelphia, Lippincott, 1991
 
27) 吉野良平: 音楽家とリウマチの訴え. リウマチ病セミナーII (七川歡次監修) J: pp. 146-154, 大阪, 永井書店, 1991
 
28) Lambert CM: Hand and upper limb problems of instrumental musicians. Br J Rheumatol 31: 265-271, 1992
PubMed
29) Kivekas J, Riihimaki H, Husman K, et al: Seven-year follow-up white-finger symptoms and radiographic wrist findings in lumberjacks and referents. Scand J Work Environ Health 20: 101-106, 1994
PubMed
30) Harrington JT: Fibromuscular pain disorders in the injured worker: Accurate examination is the key to diagnosis. Wisconsin Med J 91: 585-587, 1992
PubMed
31) 本郷一郎: 結合組織炎症候群. リウマチ病セミナーI (七川歡次監修), pp. 95-111, 大阪, 永井書店, 1990
 
32) 西岡淳一: Fibromyalgiaのレゾンデートル. リウマチ病セミナーV (七川歡次監修), pp. 69-77, 大阪, 永井書店, 1994
 
33) White KP, Harth M, Teasell RW: Work disability evaluation and the fibromyalgia syndrome. Semin Arthritis Rheum 24: 371-381, 1995
PubMed
34) Travell JG, Simons DG: Myofascial pain and dysfunction. The trigger point manual. Vol 1. The upper extremities. Vol 2. The lower extremities. Baltimore, Williams &Wilkins, 1992
 

検査法

P.139 掲載の参考文献
1) Heaney RP, Avioli LV, Chesnut C3, et al: Osteoporotic bone fragility. Detection by ultrasound transmission velocity. Jama 261: 2986-2990, 1989.
 
2) Rossman P, Zagzebski J, Mesina C, et al: Comparison of speed of sound and ultrasound attenuation in the os calcis to bone density of the radius, femur and lumbar spine (see comments). Clin Phys Physiol Meas 10: 353-360, 1989.
 
3) 游逸明, 山本逸雄, 大中恭夫ら: 超音波を使用した踵骨骨強度測定の臨床的有用性について. 日放学誌53: 1340-1346, 1993.
 
4) Ashman RB, Corin JD, Turner CH: Elastic properties of cancellous bone: measurement by an ultrasonic technique. J Biomechanics 20: 979-986, 1987.
 
5) Gluer CC, Wu CY, Genant HK: Broadband ultrasond attenuation signals depend on trabecular orientation: an in vitro study. Osteoporosis Int 3: 185-191, 1993.
 
6) Antich PP;Ultrasound study of bone in vitro. Calcif Tissue Int 1993.
PubMed
7) Yamazaki K, Kushida K, Ohmura A, et al: Ultrasond bone densitimetry of the os calcis in Japanese women. Osteoporosis Int 4: 220-225, 1994.
 
8) 游逸明, 山本逸雄, 高田政彦ら: 超音波法を用いた骨量評価法について. Ther Res 13: 3899-3907, 1992.
Medical*Online
9) 福永仁夫: 健常女性における低周波超音波による踵骨の骨量パラメータの測定. 平成5年度長寿科学総合研究報告書, pp131-134, 1993.
 
10) Gluer CC, Cummings SR, Bauer DC, et al: Association between quantitative ultrasound and recent fractures. J Bone Miner Res 9: s153, 1994.
 
11) Sakata S, Kushida K, Yamazaki K, et al: Ultrasound bone densitimetry of the os calcis in elderly women with hip fracture. J Bone Miner Res 9: s334, 1994.
 
12) Vogel J, Huang C, Ross PD, et al: Broadband ultrasound attenuation (BUA) predicts risk of vertebral fractures. J Bone Miner Res 9: s154, 1994.
 
13) 田崎正善, 岡本不二子, 中江初恵ら: 骨粗鬆症の検診方法-超音波法-. 公衆衛生58: 397-401, 1994.
 
14) 山本逸雄, 游逸明, 中島言子ら: 踵骨超音波法による骨粗鬆症検診Osteoporosis Jap 2: 235-240, 1994,
 
15) Hans D, Dargent P, Schott AM, et al: Ultrasound parameters predict hip fracture independently of hip bone density: The EPIDOS prospective study. J Bone Mineral Res 10 (suppl 1) s169, 1995.
 
P.147 掲載の参考文献
1) 小野村敏信, 瀬本喜啓: 超音波の整形外科応-その経緯と特性-. 骨・関節・靭帯5: 413-419, 1992
 
2) 山下文治, 寺内和樹, 平澤泰介: 慢性関節リウマチの手指関節および腱の超音波検査. 日整会誌65 (2): S314, 1991
 
3) 玉井和哉, 大野弥, 長谷川恭弘ら: 慢性関節リウマチの膝関節に対する超音波検査. 日本整形外科超音波研究会会誌2: 81-84, 1990
 
4) 玉井和哉, 長谷川恭弘, 大野弥ら: 超音波断層像によるリウマチ膝関節軟骨の評価. 日本整形外科超音波研究会会誌3: 13-16, 1991
 
5) Aisen AM, McCune WJ, MacGuire A, et al: Sonographic evaluation of the knee. Radiology 153: 781-784, 1984
PubMed
6) McCune WJ, Dedrick DK, Aisen AM, et al: Sonographic evaluation of osteoarthritic femoral condylar cartilage. Correlation with operative findngs. Clin Orthop 254: 230-235, 1990
 
7) 種田陽一, 松井宣夫, 太田弘敏ら: 慢性関節リウマチにおけるpopliteal cyst及びcalf cystの超音波断層診断. 中整災誌31: 1900-1902, 1988
 
P.154 掲載の参考文献
1) Nienhuis RLF, Mandema E: A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 23: 302-305, 1964
 
2) Hoet RM, Venrooij WJ: The antiperinuclear factor (APF) and antikeratin antibody (AKA) in rheumatoid arthritis. In Rheumatoid Arthritis (Ed, Smolen et al). pp300-318, Berlin Heidelberg, Springer-Verlag, 1992
 
3) Youinou P, Legoff P: The reliability of the antiperinuclear factor test despite the inconstancy of the targeted antigens. J Rheumatol 21: 1990-1991, 1994
 
4) Young BJJ, Mallya RK, Leslie RDC, et al: Antikaratin antibodies in rheumatoid arthritis. Br Med J 2: 97-99, 1979
 
5) Sarax A, Valls I, Voisin V, et al: How useful are tests for rheumatoid factors, antiperinuclear factors, antikeratin antibody, and the HLA DR4 antigen for the diagnosis of rheumatoid arthritis? Revue Rhum [Engl Ed] 62 (1) 116-20, 1995
 
6) Cordonnier C, Meyer O, Palazzo E, et al: Diagnotic value of anti-RA 33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 35: 620-624, 1996
 
7) Imanaka H, Takei S, Hokonohara M: Diagnostic value of anti-keratin antibodies in patients with juvenile rheumatoid arthritis. Jap J Rheumatol 4: 225-235, 1993
 
8) Adebajo AO, Hazleman BL: Diagnostic role of antikeratin antibodies in RA. Ann Rheum Dis 51: 1264, 1992
PubMed
9) Aho K, Von Esen R, Kurki P, et al: Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988
 
10) Simon M, Girbal E, Sebbag M, et al: The cytokeratin filament-aggregating protein filaggrin is the target of the so-called"antikeratin antibodies", autoantibodies specific for the rheumatoid arthritis. J Clin Invest 92: 1387-1393, 1993
PubMed
11) Aho K, Steiner G, Kurki P, et al: Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol 11: 645-647, 1993
 
12) Hassfeld W, Steiner G, Graninger W, et al: Autoantibody to the nuclear antigen RA33: amarker for early rheumatoid arthritis. Brit J Rheumatol 32: 199-203, 1993
 
13) Meyer O, Tauxe F, Fabregas D, et al: Anti-RA33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 11: 473-478, 1993
PubMed
14) Menard HA, Boire G, Lopez-longo FJ, et al: A novel antigen-antibody system restricted to rheumatoid arthritis patients. The Sa system (abstr). Arthritis Rheum (suppl) 32: S105, 1989
 
15) 志方幸道, 水落次男: 慢性関節リウマチにおけるアプローチ, リウマチ病セミナーVI (七川歡次監修), pp. 184-193, 大阪, 永井書店, 1995
 
16) Parekh R, Roitt I, Isenberg D, et al: Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1: 966-969, 1988
PubMed
17) 水落次男: 早期リウマチにおけるリウマチ因子の測定. リウマチ科 12: 337-343, 1994
 
18) Shmerling RH, Delbanco TL: How useful is the rheumatoid factor?Ach Intern Med 152: 2417-24 20, 1992
 
19) Despres N, Neyer O, Fabregas CD: The Sa system: a novel antigen antibody system specific for rheumatoid arthritis, J Rheumatol 21: 1027-1033, 1994
 
20) Westgeest A, Boerbooms A, Jongmans M, et al: Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 14: 893-897, 1987
PubMed
21) Aho K, Palusuo T, Kurki P: Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications, Semin Arthritis Rheum 23: 379-387, 1994
PubMed
22) Combe B, Eliaou JF, Daures JP, et al: Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 34: 529-534, 1995
PubMed
23) Hoet RMA, Boerbooms AMT, Arends M, et al: Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann rheum Dis 50: 611-618, 1991
 
24) Paimela L, Gripenberg M, Kurki P, et al: Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann rheum Dis 51: 743-746, 1992
PubMed
25) Kerstens P, Boerbooms A, Jeurissen M, et al: Antiperinuclear factor and disease activity in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. J Rheumatol 21: 2190-2194, 1994
PubMed

生物学的反応

P.166 掲載の参考文献
1) Rakestraw NW: Chemical factors in fatigue. I. The effect of muscular exercise upon certain common blood constituents. J Biol Chem 47: 565-591, 1921
 
2) Quick AJ: The effect of exercise on the excretion of uric acid. J Biol Chem 110: 107-112, 1935
 
3) Nichols J, Miller AT, Jr, Hiatt EP: Influence of muscular exercise on uric acid excretion in man. J Appl Physiol 3: 501-507, 1950
 
4) Knochel JP, Dotin LN, Hamburger RJ: Heat stress, exercise, and muscle injury: effects on urate metabolism and rena1 function. Ann Int Med 81: 321-328, 1974
 
5) Sutton JR, Toews CJ, Ward GR, et al: Purine metabolism during strenuous muscular exercise in man. Metabolism 29: 254-260, 1980
PubMed
6) 河野典夫: 筋原性高尿酸血症. 日本医事新報3442: 23-28, 1990
 
7) 河野典夫;筋原性高尿酸血症-筋・赤血球・肝におけるプリンリレー代謝-. 臨床化学25: 362-369, 1989
 
8) 河野典夫: 筋運動による高尿酸血症-筋原性高尿酸血症の概念-. 臨床科学30: 1315-1321, 1994
 
9) 河野典夫: 運動と高尿酸血症のかかわり-その臨床的意義と適切な対応-. Medical Practice 12: 685-689, 1995
 
10) 河野典夫: 二次性高尿酸血症. 高尿酸血症と痛風2143-51, 1994
 
11) 河野典夫: グリコーゲン病V型, VI型, VII型, 1m型, 最新内科学大系8, 代謝疾患3 (井村裕夫他編), pp 111-123, 東京, 中山書店, 1996
 
12) Kono N, Mineo I, Shimizu T, et al: Increased plasma uric acid after exercise in muscle phosphofructokinase deficiency. Neurology 36: 106-108, 1986
PubMed
13) Mineo I, Kono N, Hara N, et al: Myogenic hyperuricemia: a common pathophysiologic feature of glycogenosis types III, V and W, N Engl J Med 317: 75-80, 1987
 
14) Kono N, Mineo I, Sumi S, et al: Metabolic basis of improved exercise tolerance: muscle phosphorylase deficiency after glucagon administration. Neurology 34: 1471-1476, 1984
PubMed
15) Mineo I, Kono N, Shimizu T, et al: Excess purine degradation in exercising muscles of patients with glycogen storage disease typesV and VII. J Clin Invest 76: 556-560, 1985
PubMed
16) Mineo I, Kono N, Yamada Y, et al: Glucose infusion abolishes the excessive ATP degradation in working muscles of a patient with McArdle: s disease. Muscle Nerve 13: 618-620, 1990
PubMed
17) Ono A, Kuwajima M, Kono N, et al: Glucose infusion paradoxically accelerates degradation of adenine nucleotide in working muscle of patients with glycogen storage disease type VII. Neurology 45: 161-164, 1995
PubMed
18) 姜進, 曽我文久: Mitochondrial myopathy. In: リウマチ病セミナーVI (七川歡次監修), pp. 32-40, 大阪, 永井書店, 1995
 
19) Hara N, Mineo I, Kono N, et al: Enhanced release of ammonia and hypoxanthine from exercising muscles in patients with idiopathic hypoparathyroidism. Muscle Nerve 10: 599-602, 1987
PubMed
20) Shimizu T, Kono N, Kiyokawa H, et al: Erythrocyte glycolysis and its marked alteration by muscular exercise in type VII glycogenosis. Blood 71: 1130-1134, 1988
PubMed
21) Laundry F, Orban WAR: 3rd International Symposium on Biochemistry of Exercise. Vo13, Symposia Specialists, USA, 1978
 
22) Nishimura T, Shimizu T, Mineo I, et al: Influence of daily drinking habits on ethanol-induced hyperuricemia. Metabolism 43: 745-748, 1994
PubMed
23) Kono N, Tarui S: Muscle glycogenoses. In: Inborn Metabolic Disease. Diagnosis and Treatment (Ed, Fernandes J, et al), pp. 89-94, Heiderberg, Springer-Verlag, 1990
 
24) Becker MA, Roessler BJ: Hyperuricemia and gout. In: Metabolic and Molecular Basis of lnherited Disease (Ed, Scriver CR, et al: , pp. 1655-1677, New York, McGraw-Hill, 1995
 
P.174 掲載の参考文献
1) Hammer RE, Maika SD, Richardson JP, et al: Spontaneous inflammatory disease in transgenic rats exessing HLA-B27 and human Bm: an animal model of HLA-B27 associated human disorders. Cell 63: 1099-1112, 1990
 
2) Khare SD, Lurhra HS, David CS: Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking B2-microglobulin: a model of human spondyarthropathies. J Exp Med 182: 1153-1158, 1995
 
3) Taniguchi T: Cytokine signaling rhrogh nonreceptor protein tyrosine kinases. Science 268: 251-255, 1995
PubMed
4) Tatake RJ, Zeff RA: Regulated expression of the major histocompatibility complex class I genes. PSEBM 203: 405-417, 1993
 
5) Kopp EB, Ghosh S: NF-kB and rel proteins in innate immunity. Adv Immunol 58: 1-27, 1995
PubMed
6) Bovolenta C, Driggers PH, Marks MS, et al: Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci 91: 5046-5050, 1994
PubMed
7) Dey A, Thornyon AM, Lonergan M, et al: Occupancy of upstream regulatory sites in vivo coincides with major histocompatibility complex class I gene expression in mouse tissues. Mol Cell Biol 12: 3590-3599, 1992
 
8) Park JH, Lee HW, Fleischhauer KL, et al: DNA-binding proteins for transciption enhancing region of HLA class I gene. Tissue Antigens 42: 78-86, 1993
 
9) Stein B, Baldwin Jr AS, et al: Cross-coupling of the NF-kB p65 and fos/jun transcrirtion factros produces potentiated biological funtion. EMBO J 12: 3879-3891, 1993
 
10) Handel ML, Mcmorrow LA, Gravallese EM: Nuclear factor-kB in rheumatoid synovium. Arthritis Rheum 38: 1762-1770, 1995
 
11) Sengupta TK, Chen A, Zhong Z, et al: Activation of monocyte effector genes and STAT family transcreption factors by inflammatory synovial fluid is independent of interferon 7. J Exp Med 181: 1015-1025, 1995
 
12) Hill CS, Treisman R: Transcriptional regulation by extracellular signals: mechanism and specificity. Cell 80: 199-211, 1995
PubMed
13) Lee JC, Laydon JT, McDonnell PC, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994
PubMed
14) Kopp E, Ghosh S: Inhibition of NF-kB by sodium salicylate and aspirin. Science 265: 956-959, 1994
PubMed
15) Macilwaim C: Aspirin on trial as HIV treatment. Nature 364: 369, 1993
 
16) Scheinman RI, Cogswell PC, Lofquist AK, et al: Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 270: 283-286, 1995
 
P.183 掲載の参考文献
1) 西村慶子, 米原伸: 抗Fas抗体を利用した自己免疫疾患モデルマウスの治療実験.Mebio 12: 109-116, 1996
 
2) Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1996
 
3) Chu K, Niu X, Williams LT: AFas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci USA 92: 11894-11898, 1995
 
4) Wu J, Zhou T, Zhang J, et al: Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA 91: 2344-2348, 1994
 
5) Memon SA, Moreno MB, Petrak D, et al: Bcl-2blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T cell hybridoma. J Immunol 155: 4644-4652, 1995
 
6) Parijs LV, Ibraghimov A, Abbas AK: The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4: 321-328, 1996
 
7) Tsuboi M, Eguchi K, Kawakami A, et al: FAS antigen expression on synovial cells was down-regulated by interleukin 1β, Biochem Biophys Res Commun 218: 280-285, 1996
 
8) Henkart PA: ICE family proteases: mediators of all apoptotic cell death. Immunity 4: 195-201, 1996
PubMed
9) Kuida K, Lippke JA, Ku G, et al: Altered cytokine export and apoptosis in mice deficient in interleukin-1βconverting enzyme. Science 267: 2000, 1995
 
10) Klas C, Debatin KM, Jonker RR, et al: Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5: 625-630, 1993
 
11) Rothstein TL, Wang JKM, Panka DJ, et al: Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374: 163-165, 1995
 
12) Kagi D, Vignaux F, Ledermann B, et al: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265: 528-530, 1994
PubMed
13) 鍔田武志: 自己免疫疾患におけるB細胞アポトーシス異常. 医学のあゆみ170: 135-138, 1994
 
14) Abbas AK: Die and let live: eliminating dangerous lymphocytes. Cell 84: 655-657, 1996
PubMed
15) Willerford DM, Chen J, Ferry JA, et al: Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid component. Immunity 3: 521-530, 1995
 
16) Mysler E, Bini P, Drappa J, et al: The apoptosis-1/Fas protein in human systemic Iupus erythematosus. J Clin Invest 93: 1029-1034, 1994
 
17) Cheng J, Zhou T, Liu C, et al: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994
 
18) Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152: 3685-3692, 1994
PubMed
19) Ohsako S, Hara M, Harigai M, et al: Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathl 73: 109-114, 1994
PubMed
20) Graninger WB: Transcriptional overexpression of the protooncogene bcl-2 in patients with systemic lupus erythematosus. Wien Klin Wochenschr 104: 205-207, 1992
PubMed
21) Tax WJM, Kramers C, van Bruggen MCJ: Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 48: 666-673, 1995
 
22) Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317-1330, 1994
PubMed
23) Firestein GS, Yeo M, Zvaifler NJ: Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96: 1631-1638, 1995
PubMed
24) Nakajima T, Aono H, Hasunuma T, et al: Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485-491, 1995
PubMed

治療と副作用

P.194 掲載の参考文献
1) 篠田壽: ビスホスホネートの骨吸収抑制作用. 日薬理誌105: 285-294, 1995
 
2) Fleisch H: Bisphosphonates: mechanism of action and clinical use. In: Handbook of Experimental Pharmacology, Vol 107, Physiology and Pharmacology of Bone (Ed, Mundy GR, Martin TJ), pp. 377-418, Springer-Verlag, Berlin, Heidelberg, 1993
 
3) Carano A, Teitelbaum SL, Konsek JD, et al: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85: 456-461, 1990
PubMed
4) Schenk R, Eggli P, Fleisch H, et al: Quantative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rats. Calcif Tissue Int 38: 342-349, 1986
 
5) Muhlbauer RC, Bauss F, Schenk R, et al: BM 21. 0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003-1011, 1991
PubMed
6) 村上博志, 高橋直之, 宇田川信之ら: チルドロネートは破骨細胞のチロシンポスファターゼ活性を阻害し, 骨吸収を抑制する. 日骨代謝誌13 (抄録号): 97, 1995
 
7) Francis MD, Flora L, King WR: The effects of disodium ethane-1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tisue Res 9: 109-121, 1992
 
8) Glatt M, Blatter A, Bisping M, et al: Effects of diphosphonates (APD, EHDP) on inflammation and bone turnover in adjuvant arthritis rats. Experimentia 39: 681
 
9) Francis MD, Hovancik K, Boyce RW: NE-58095: adiphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React XI: 239-252, 1989
 
10) Osterman T, Kippo K, Lauren L, et al: Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14: 139-147, 1994
PubMed
11) 廣畑和志, 中野謙吾, 中島咲哉ら: 股関節形成術後の異所性骨化に対するEtidronate Disodium (EHDP) の臨床効果について. 基礎と臨床23: 1449-1461, 1989
 
12) Katsumata T, Nakamura T, Ohnishi H, et al: Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 10: 921-931, 1995
PubMed
13) Seedor JG, Quartuccio HA, Thompson DD: The bisphosphonate attendronate (MK-217) inhibits boneloss due to ovariectomy in Rats. J Bone Miner Res 6: 339-346, 1991
 
14) Ammann P, Rizzoli R, Caverzasio J, et al: Effects of the bisphosphonate tiludtonate on bone resorption, calcium balance, and Bone Mineral Density. J Bone Miner Res 811491-1498, 1993
 
15) Balena R, Toolan BC, Shea M, et al: The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histmorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2586, 1993
 
16) Storm T, Thamsberg G, Steiniche T, et al: Effects of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteporosis. N Engl J Med 322: 1265-1271, 1990
 
17) Watts NB, Harris ST, Genant HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteporosis. N Engl J Med 323: 73-79, 1990
 
18) 藤田拓男, 折茂肇, 井上哲郎ら: 退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸ナトリウム(EHDP)の二重盲検比較試験. Clin Eval 21: 261-302, 1993
 
19) Liberman UA, Weiss SR, Broll J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteporosis. N Engl J Med 333: 1437-1443, 1995
 
20) Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944, 1991
PubMed
21) Van Lent PLEM, van den Bersselaar, Holthuyzen AEM, et al: Phagocytic synovial lining cells in experimentally induced chronic arthritis: down-regulation of synovitis by CL2MDP-liposomes. Rheumatol Int 13: 221-228, 1994
 
22) Eggelmeijer F, Papapoulos SE, van Paassen HC, et al: Clinical and biochemical response to single infusion of pamidronate in patients with antive rheumatoid arthritis: a double blind placebo controlled study. Rheumatol 21: 2016-2020, 1994
 
P.202 掲載の参考文献
1) Cobb S: The Frequency of the Rheumatic Diseases. Cambridge, Harvard, 1971
 
2) Lawrence JS: Rheumatism in Populations. London, Heinemann, 1977
 
3) Chrousos GP: Molecular and endocrine mechanisms of the stress response. NIH Conferance: The stress response and the regulation of inflammatory deisease. Ann Intern Med 117: 854-857, 1992
 
4) 松村繁: 神経内分泌免疫学序説. 感染, 炎症, 免疫26: 94-101, 1995
 
5) Okabayashi A, Kondo Y, Tada T: In: Masugi Nephritis and Its Immunopathologic Implications (Ed, Okabayashi A, Kondo Y), pp. 162-182, Tokyo, Igaku-Shoin, 1980
 
6) Sternberg EM, Hill JM, Chrousos GP, et al: Inflammatory mediator-induced hypothalamicpituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci 86: 2374-2378, 1989
 
7) Sternberg EM, Young W 3 rd, Bernardini R, et al: Acentral nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall arthritis in Lewis rats. Proc Natl Acad Sci 86: 4771-4775, 1989
 
8) Masi AT, Feigenbaum SL, Chatterton RT: Hormonal and pregnancy relationships to rheumatoid arthritis: Convergent effects with immunologic and microvascular systems. Semin Arthritis Rheum 25: 1-27, 1995
PubMed
9) Hernandez-Avila M, Liang MH, Willett WC, et al: Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum 33: 947-953, 1990
PubMed
10) Sepector TD, Hochberg MC: The protective effect of the oral contraceptive pill on rheumatoid arthritis: An overveiw of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 43: 1221-1230, 1990
 
11) Linos A, Worthington JW, O'Falon WM, et al: The epidemiology of rheumatoid arthritis in Rochester, Minnesota: Astudy of incidence, prevalence and mortality. Am J Epidemiol 111: 87-98, 1980
 
12) Silman AJ, Roman E, Beral V, et al: Adverse reproductive outcomes in women who subsequently develop rheumatoid arthritis, Ann Rheum Dis 47: 979-981, 1988
PubMed
13) Shichikawa K, Hirota S, Inoue K, et al: Incidence of rheumatoid arthritis in a population of Kamitonda district, Wakayama, Japan. Rev Rhum [Egnl Ed] 62: 713, 1995 (abstract)
 
14) Dugowson CE, Koepsell TD, Voigt LF, et al: Rheumatoid arthritis in women: incidence rates in a group health co-operative, Seattle, Washingon 1987-1989. Arthritis Rheum 34: 1502-1507, 1991
 
15) 七川歡次, 今中徹: この30年間における慢性関節リウマチの変貌. リウマチ病セミナーII (七川歡次監修), 大阪, 永井書店. pp. 88-96, 1991
 
16) 後藤真: 慢性関節リウマチの発症要因としての加齢. リウマチ科12: 51-60, 1994
 
17) Vandenbroucke JP, Witteman JCM, Valkenburg HA, et al: Noncontraceptive hormones and rheumatoid arthritis in premenopausal and postmenopausal women. JAMA 255: 1299-1303,
 
18) Carette S, Marcoux S, Gingras S: Postmenopausal hormones and the incidence of rheumatoid arthritis. J Rheumatol 16: 911-913, 1989
PubMed
19) Spector TD, Brennan P, Harris P, et al: Does estrogen replacement therapy protect agonist rheumatoid arthritis? J Rheumatol 18: 1437-1446, 1991
 
20) 大田寛, 七川歡次, 前田晃ら: 慢性関節リウマチの死因調査 (340死亡例). 平成6年度特定疾患調査研究結果報告書, 骨. pp. 1-10, 大阪府環境保健部, 大阪骨. 関節難病研究会. 平成7年3月, 1995
 
21) 廣田茂永, 七川歡次, 井上康二ら: 住民調査による慢性関節リウマチ患者例と病院例との自然経過の比較. 第10回日本臨床リウマチ学会, 抄録集, p. 98, 1995
 
22) 辻林啓吉, 膳棟造, 津山研一郎ら: 在宅ねたきりRA患者の死亡調査-和歌山県南紀地区-. 臨床リウマチ 4: 145-149, 1991
 
23) Solomon L, Robin G, Valkenburg, HA: Rheumatoid arthritis in an urban South Africa n Negro population. Ann Rheum Dis 34: 128-135, 1975
 
24) Beighton P, Solomon L, Valkenburg, HA: Rheumatoid arthritis in a rural South African negro population. Ann Rheum Dis 34: 136-141, 1975
 
25) 斎藤潤;慢性関節リウマチの生物学的マーカー. リウマチ病セミナーVII (七川歡次監修), pp. 148-155, 大阪, 永井書店, 1996
 
26) 前田晃: 亜急性関節リウマチについて. リウマチ病セミナーVI (七川歡次, 監修), pp. 15-20, 大阪, 永井書店, 1995
 
27) 前田晃: RAと食事療法. リウマチ病セミナーVII(七川歡次監修), pp. 205-215, 大阪, 永井書店, 1996
 
28) 清水源一郎, 滝内勝男: 関節リウマチのビールス説の検討. 日外会誌50: 112, 1949
 
29) Shimizu G, Shichikawa K, Takeuchi K: Studies on the etiology of rheumatoid arthritis. 1. Comments on infections theory. Med J Osaka Univ 7: 413-427, 1956
 
30) 村井千尋, 佐々木毅: ホトパルボウイルスB19 (HPV/B19) のリウマチ症状. リウマチ病セミナーV (七川歡次, 監修), pp. 3-9, 1994
 
31) 安波礼子: 慢性関節リウマチとHLA. リウマチ病セミナーVI (七川歡次, 監修), pp. 215-221, 大阪, 永井書店, 1995
 
32) Jarvinen P, Aho K: Twin studies in rheumatic diseases. Semin Arthritis Rheum 24: 19-28, 1994
 
P.212 掲載の参考文献
1) Bahna S, Kanega J: Food hypersensitivity. Rheum Dis Clin Nor Amer 17: 243-250, 1991
 
2) Darlington LG: Dietary therapy for arthritis. Ibid 17: 273-286, 1991
 
3) Panush RS: Does food cause or cure arthritis. Ibid 17: 259-272, 1991
 
4) Weatherby M: Chronic arthritis. The clinical analysis of three hundred and fifty cases. AMA Arch Intern Med 50: 926-994, 1932
 
5) Minot GR: General aspects of the treatment of chronic arthritis. N Engl J Med 208: 1285-1290, 1933
 
6) Hench BS, Bauer W, Boland E, et al: Rheumatoid arthritis: Review of the American and English literature for 1940. Ann Intern Med 15: 1002-1108, 1941
 
7) Hansen TM, Lorche A, Kussis V, et al: Treatment of rheumatoid arthritis with prostaglandin El precursores cislinoleic acid and α-linolenic acid. Scand J Rheum 2: 85-88, 1983
 
8) Panush RS, Carter RL, Katz P, et al: Diet therapy for rheumatoid arthritis. Arthritis Rheum 26: 462-471, 1983
PubMed
9) Zeller M: Rheumatoid arthritis-food allergy as a factor. Ann Allergy 7: 200-230, 1949
PubMed
10) Zussman BM: Food hypersensitivity stimulating rheumatoid arthritis. South Med J 59: 935-939, 1966
 
11) Rowe AH: Food allergy and arthropathy. In: Food Allergy (Ed, Thomas CC, et al), pp. 4355-4443, Springfield IL, 1972
 
12) Randolph TC: Ecologically oriented rheumatoid arthritis. In: Food Allery (Ed, Dickey LD, Thomas CC), pp. 201-212, Springfield IL, 1976
 
13) Parke AL, Hugdhes GRV: Rheumatoid arthritis and food: Acase study. Br Med J 282: 2027-2029, 1981
 
14) Wraith DG: Allergic joint symptoms. Presented at the 4th International Food Allergy, Symposium of American College of Allergy, Vancouver, Canada, 1982
 
15) Ratner P, Schneeyour A, Eshel E, et al: Does milk intolerance affect seronegative arthritis in lactose-deficient women?Israel J Med Sci 21: 532-534, 1985
 
16) Panush RS, Stroud RM, Webster E: Food-induced (allergic) arthritis. Inflammatory arthritis exacerbated by milk. Arthritis Rheum 29: 220-229, 1986
PubMed
17) Tanner SB, Callahan LF, Panush RS, et al: Self report of 704 rheumatoid arthritis patients regarding the impact of specific types of foods on disease. Arthritis Rheum 30: 542, 1987
 
18) O'Farrelly C, Melcher D, Price R, et al: Association between villous atrophy in rheumatoid arthritis and a rheumatoid factor and gliadin-spific Ig. Lancet ii: 819, 1988
 
19) 前田晃, 松平敏子:慢性関節リウマチと食事, 大阪府特定疾患研究会平成7年度報告書 (印刷中).
 
20) Skoldstam L, Larsson M, Lindstrom FD: Effects of fasting and lactovegetarian diet on rheumatoid arthritis. Scand J Rheum 8: 249-256, 1979
 
21) Sundqvist T, Lindstrom F, Magnusson KE, et al: Influence of fasting on intestinal permeability and disease activity in patients with rheumatoid arthritis. Scand J Rheum 11: 33-38, 1982
PubMed
22) Stroad RM: The effect of fasting followed by specific food challenge on rheumatoid arthritis. In: Current Topics in Rheumatology, pp.145-157, Upjohn, 1983
 
23) Uden AM, Trang L, Venizelos N, et al: Neutrophil functions and clinical performance after total fasting in patients with rheumatoid arthritis. Ann Rheum Dis 42: 593-604, 1983
 
24) Hafstrom L, Ringertz B, Gyllenhammar, et al: Effect of fasting on disease activity, neutrophil function, fatty acid composition, and leucotriene biosynthesis in patients with rheumatoid arthritis. Arthritis Rheum 31: 585-592, 1988
 
25) Palmblad J, Hafstrom I, Ringertz B: Antirheumatic effects of fasting. Rheum Dis Clin Nor Amer 17: 351-362, 1991
 
26) Skoldstam L, Magnusson KE: Fasting, intestinal permeability, and rheumatoid arthritis. Ibid 17: 363-371, 1991
 
27) Hicklin JA, McEwen LM, Morgan JE: The effect of diet in rheumatoid arthritis. Clin Allergy 10: 463, 1980
 
28) Denman AM, Mitchell B, Ansell BM: Joint complaints and food allergic disorders. Ann Allergy 51: 260, 1983
PubMed
29) Kroker GP, Stroud RM, Marchall RT: Fasting and rheumatoid arthritis. (Ed, Thomas CC). pp. 137, Clinical Ecology, Springfield, IL 1984
 
30) Kremer JM, Bigauoette J, Michalek AU, et al: Effect of manipulating dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1: 184-187, 1985
 
31) Kremer JM, Jubiz W, Michalek AU, et al: Fish oil fatty acid supplementation in active rheumatoid arthritis. Ann Intern Med 106: 497-503, 1987
 
32) Kremer JM: Clinical studies of omega 3 fatty acid supplementation in patients who has rheumatoid arthritis. Rheum Dis Clin Nor Amer 17: 391-402, 1991
 
33) Kremer JM, Lawrence DA, Petrillo GF, et al: Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal anti-inflammatory drugs. Arthritis Rheum 38: 1107-1114, 1995
PubMed
34) Sperling RI, Weinblatt M, Robin JL, et al: Effects of dietary supplementation with marine fish oil on leucocyte lipid mediator generation and function in rheumatoid arthritis. Arthrits Rheum 30: 988-997, 1987
 
35) Cleland LG, French JK, Betts WH, et al: Clinical and biochemical effects of dietary fish oil supplement in rheumatid arthritis. J Rheumatol 15: 1471-1475, 1988
 
36) Belch JJF, Ansell D, Madkok R, et al: Effects of altering dietary essential fatty acids on requirement for nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Ann Rheum Dis 47: 96-104, 1988
 
37) Templ HV, Tulleken JE, Limburg PC, et al: Effect of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis 49: 76-80, 1990
 
38) 谷口敦夫: 慢性関節リウマチの食事療法, リウマチ病セミナーI (七川歡次監修), pp. 3-11, 大阪, 永井書店, 1990
 
39) Panush RS: American College of Rheumatology, position statement"Diet and Arthritis". Rheum DIS Clin Nor Amer 17: 443-447, 1991
 
40) Yoshino S, Quattrocchi E, Weiner HL: Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum 38: 1092-1096, 1995
PubMed
41) Tompson HSG, Henderson B, Spencer JM, et al: Tolerogenic activity of polymerized type II collagen in preventing collagen-induced arthritis in rats. Clin Exp Immunol 72: 20-25, 1988
 
42) Tompson SJ, Tompson HSG, Happer N, et al: Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunol 79: 152-157, 1993
 
43) Zhang ZJ, Lee C, Lider O, et al: Suppression of adjuvant arthritis in Lewis rats by oral administration of type H collagen. Arthritis Rheum 32: S106, 1990
 
44) Zhang ZJ, Alsabbagh A, Lorenzo C, et al: Suppression of adjuvant and collagen-induced arthritis by aerosol administration of collagen type II. Arthritis Rheum 32: S106, 1990
 
45) Trentham DE, Trentham RA, Orav EJ, et al: Effects of oral administration of type II collagen. Science 261: 1727-1730, 1993
 
46) Hafler DA: Oral tolerance in autoimmune diseases. Ann Rheum Dis 54: 761, 1995
 
47) Sieper J, Kaig S, Mitchison NA: Results of german study of oral tolerance. Ann Rheum Dis 54: 761, 1995
 
48) Vischer TL, van Eden W: Oral desensitization in rheumatoid arthritis. Ann Rheum Dis 53: 708-710, 1994
PubMed
49) Vischer TL: Double blind multicenter study of OM-8980 and auranofin in rheumatoid arthritis. Ann Rheum Dis 47: 582-587, 1988
PubMed
50) Brackertz D, Vischer TL: OM-8980 in rheumatoid arthrits: A6-month double blind placebo controlled multicentre study. J Rheumatol 16: 19-23, 1989
 
51) Kingsley GH, Lanchbury J, Panayi GS: Symposium on immunotherapy. Ann Rheum Dis 54: 757-778, 1995
 
P.222 掲載の参考文献
1) Sinnett MJ, Groff GD, Raddatz DA, et al: Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 16: 745-748, 1989
PubMed
2) Bologna C, Endo L, Anaya, J-H, et al: Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 37: 1770-1773, 1994
 
3) 中島亜矢子, 箱田雅之, 柏崎禎夫: メトトレキサートの抗リウマチ作用発現機序. シンポジウム炎症と免疫 3: 160-166, 1994
 
4) 佐京かつふみ: 慢性関節リウマチにおけるメトトレキサートの作用機序. Connective Tissue 27: 159-166, 1995
Medical*Online
5) Sperling RI, Benincaso AI, Anderson RJ, et al: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35: 376-384, 1992
PubMed
6) Leroux JL, Damon M, Chavis C, et al: Effects of a single dose of methotrexate on 5-and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 19: 863-866, 1992
 
7) Hawkes JS, Cleland LG, Proudman SM, et al: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 21: 55-58, 1994
PubMed
8) Kremer JM, Jubiz W, Michalek A, et al: Fish oil fatty acid supplementation in active rheumatoid arthritis. Ann Intern Med 106: 497-503, 1987
PubMed
9) Kremer JM: The mechanism of action of methotrexate in rheumatoid arthritis: The search continues. J Rheumatol 21: 1-5, 1994
PubMed
10) Laurindo IMM, Mello SBV, Cossermelli W: Influence of low doses of methotrexate on superoxide anion production by polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Rheumatol 22: 633-638, 1995
 
11) Alarcon GS, Schrohenloher RE, Bartolucci AA, et al: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33: 1156-1161, 1990
PubMed
12) Wascher TC, Hermann J, Brezinschek HP, et al: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Investg 72: 535-540, 1994
PubMed
13) Balsa A, Gamallo C, Martin-Mola E, et al: Histologic changes in rheumatoid synovitis induced by naproxen and methotrexate. J Rheumatol 20: 1472-1477, 1993
PubMed
14) Segal R, Yaron M, Tartakovsky B: Methotrexate: Mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 20: 190-200, 1990
PubMed
15) Hu S-K, Micho YL, Oronsky AL, et al: Studies on the effect of methotrexate on macrophge function. J Rheumatol 15: 206-209, 1988
 
16) Barrera P, Boerbooms AMT, Janssen EM, et al: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36: 1070-1079, 1993
 
17) Crilly A, Mclnness IB, McDonald A, et al: Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low does oral methotrexate: J Rheumatol 22: 224-226, 1995
 
18) Boerbooms AM, Kerstens PJS, van Loenhout JWA, et al: Infections during low-does methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24: 411-421, 1995
 
19) Houtman PM, Stenger AAME, Bruyn GAW, et al: Methotrexate may affect certain T lymphocyte subsets in rheumatoid arthritis resulting in susceptibility to Pneumocystis carinii infection. J Rheumatol 21: 1168-1169, 1994
 
20) Liote F, Pertuiset E, Cochand-Priollet B, et al: Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol 22: 1174-1178, 1995
 
21) Moder KG, Tefferi A, Cohen M, et al: Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: Aretrospective study. AM J Med 99: 276-281, 1995
 
22) Hirata S, Matsubara T, Saura R, et al: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-does methotrexate. Arthritis Rheum 32: 1065-1073, 1989
PubMed
23) Firestein GS, Paine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression, Arthritis Rheum 37: 193-200, 1994
PubMed
24) Chabner BA, Allegra CJ, Curt GA, et al: Polyglutamation of methotrexate. Is methotrexate a prodrug?J Clin Invest 76: 907-912, 1985
PubMed
25) Cronstein BN, Eberle MA, Gruber HE, et al: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Prc Natl Acad Sci USA 88: 2441-2445, 1991
 
26) Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin lnvest 92: 2675-2682, 1993
 
27) Firestein GS, Boyle DL, Bullough DA, et al: Protective effect of an adenosine kinase inhibitor in septic shick. J Immunol 152: 5853-5859, 1994
 
28) Firestein GS, Bullough DA, Erion MD, et al: Inhibition of neutrophil adenosine and an adenosinekinase inhibitor: the role of selectins. J Immunol 154: 326-334, 1995
 
29) Kammer GM, Birch RE, Polmar SH: Impaired immunoregulation in systemic lupus erythematosus: defective adenosine-induced suppressor T lymphocyte generation. J Immunol 130: 1706-1712, 1983
PubMed
30) Nesher G, Moore TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthrltis Rheum 33: 954-959, 1990
PubMed
31) Nesher G, Moore TL, Dorner RW: In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann Rheum Dis 50: 637-641, 1991
PubMed
32) Nakajima A, Hakoda M, Yamanaka H, et al: Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann Rheum Dis 55: 237-242, 1996
 
P.231 掲載の参考文献
1) Tanabe M, Ochi T, Tomita T, et al: Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 21: 830-835, 1994
PubMed
2) Hayashida K, Ochi T, Fujimoto M, et al: Bone marrow changes in adjuvant-induced and collageninduced arthritis. Interleukin-1 and interleukin-6activity and abnormal myelopoiesis. Arthritis Rheum 35: 241-245, 1992
 
3) Gough AK, Lilley J, Eyre S, et al: Generalised bone loss in patients with early rheumatoid arthritis[see comments]. Lancet 344: 23-27, 1994
 
4) Sambrook PN, Spector TD,: Seeman E, et al: Osteoporosis in rheumatoid arthritis. A monozygotic co-twin control study, Arthritis Rheum 38: 806-809, 1995
PubMed
5) Buckley LM, Leib ES, Cartularo KS, et al: Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22: 1055-1059, 1995
PubMed
6) Laan RF, van-Riel PL, van-de-Putte LB, et al: Low-dose prednisone induces rapid reversible axialbone loss in patients with rheumatoid arthritis. A randomized, controlled study[see comments]. Ann Intern Med 119: 963-968, 1993
 
7) Verstraeten A, Dequeker J: Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 45: 852-857, 1996
 
8) Sambrook PN, Cohen ML, Eisman JA, et al: Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48: 535-538, 1989
 
9) Leboff MS, Wade JP, Mackowiak S, et al: Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J Rheumatol 18: 339-344, 1991
PubMed
10) Nagant-de-Deuxchaisnes C, Devogelaer JP, et al: Influence of the menopausal state on the effect of low-dose glucocorticoid on bone mass in rheumatoid arthritis patients[letter]. Arthritis Rheum 29: 693-695, 1986
 
11) Sambrook PN, Eisman JA, Yeates MG, et al: Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 45: 950-953, 1986
PubMed
12) Felder M, Ruegsegger P: Bone loss in patients with rheumatoid arthtitis-effect of steroids measured by low dose quantitative computed tomography[published erratum appears in Rheumatol Int 1991: 11: 220]. Rheumatol Int 11: 41-44, 1991
 
13) Butler RC, Davie MW, Worsfold M, et al: Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy. Br J Rheumatol 30: 86-90, 1991
PubMed
14) Hall GM, Spector TD, Griffin AJ, et al: The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36: 1510-1516, 1993
 
15) 小泉雅彦, 森茂樹, 上田孝文ら: RAにおける骨粗鬆症の推移-SPA法, DIP法による骨塩定量-. 骨関節靱帯6: 863-869, 1993
 
16) Olbricht T, Benker G I Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J Intern Med 234: 237-244, 1993
 
17) Kroger H, Risteli J, Risteli L, et al: Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann Rheum Dis 52: 338-342, 1993
PubMed
18) Young A, Kinsella P, Boland P: Stress fractures of the lower limb in patients with rheumatoid arthritis. J Bone joint Surg 63-B: 239-243, 1981
 
19) Michel BA, Bloch DA, Fries JF: Predictors of fractures in early rheumatoid arthritis. J Rheumatol 18: 804-808, 1991
PubMed
20) Michel BA, Bloch DA, Wolfe F, et al: Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20: 1666-1669, 1993
PubMed
21) Spector TD, Hall GM, McCloskey EV, et al: Risk of vertebral fracture in women with rheumatoid arthritis. Bmj 306: 558, 1993
PubMed
22) Cooper C, Coupland C, Mitchell M: Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54: 49-52, 1995
PubMed
23) Hooyman JR, Melton L 3, Nelson AM, et al: Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 27: 1353-1361, 1984
 
24) McDougall R, Sibley J, Haga M, et al: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21: 1207-1213, 1994
PubMed
25) Spector TD, James IT, Hall GM, et al: Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 12: 240-244, 1993
PubMed
P.241 掲載の参考文献
1) 内田詔爾: 長期療法とコンプライアンス慢性関節リウマチと長期療法-より良きQuality of lifeのために-(本間光夫編), pp. 86-95, メディカルレビュー, 1990
 
2) 塩川優一, 廣瀬俊一, 蕨治言ら: ミゾリビンの慢性関節リウマチに対する臨床的検討 (2)-第2相長期投与試験-. 臨床医薬6: 2593-2605, 1990
 
3) 太田善介, 江澤英光, 西谷皓次ら: 新しい抗リウマチ剤MS-932の慢性関節リウマチに対する臨床的検討. 長期投与試験[中国, 四国地区]. 臨床医学 7 (suppl 2): 199-219, 1991
 
4) 御坐清允, 西岡久寿樹, 菅原幸子ら: 慢性関節リウマチに対するサラゾスルファピリジン. 腸溶剤 (PJ-306) の長期投与試験.基礎と臨床25: 67-82, 1991.
 
5) Bell MJ, Bombardier C, Tugwell P: Measurement of functional status. quality of life, and utitlty in rheumatoid arthritis. Arthritis Rheum 33: 591-601, 1990
PubMed
6) Pincus T, et al: Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnarie. Arthritis Rheum 26: 1346-353, 1983
 
7) Felson DT, Anderson JJ, Bores M, et al: The American College of Rheumatology, preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36: 729-740, 1993
 
8) Felson DT, Anderson JJ, Bores M, et al: The American College of Rheumatology preliminary, definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727-735, 1995
 
9) 柏崎禎夫, 山中寿, 松田裕子: Prospective studyによる早期RAの病態別治療指針のための研究pp. 145-146, 平成6年度 厚生省リウマチ調査研究事業研究報告書
 
10) Scott DL, Panayi GS, Van Rieal PLCM, et al: Disease activity in rheumatoid arthritis;preliminary report of the consensus study group of the European workshop for rheumatology research. Clin Exp Rheumat 10: 521-525, 1992
 
11) Paulus HE, Egger MJ, Ward JR, et al: Analysis of improvement individual rheumatoid arthritis patients treated with disease modifying antirheumatic drugs based on the findings in patients with placebo. Arthritis Rheum 33: 477-476, 1990
PubMed
12) Van der Heijde DMFM, Vant Hof MA, Van Riel PLCM, et al: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a activity score. Ann Rheum Dis 49: 921-925, 1990
 

手術

P.251 掲載の参考文献
1) Ochi T, Iwase R, Yonemasu K, et al: Natural course of joint destruction and fluctuation of serum Clq levels in patients with rheumatoid arthritis. Arthrtis Rheum 31: 37-43, 1988
 
2) Kaukonen J-P, Raunio P: Total ankle replacement in rheumatoid arthritis: a preliminary review of 28 arthroplasties in 24 patients. Ann Chir Gynaecol 72: 196-199, 1983
PubMed
3) Newton E III: Total ankle arthropalsty. Clinical study of fifty cases. J Bone Joint Surg (A) 64-A: 104-111, 1982
 
4) Clayton ML: Management of the rheumatoid ankle. In: Surgery for Rheumatoid Arthritis (Ed, Clayton ML, et al), pp. 295-305, Edinburgh, Churchill Livingstone, 1992
 
5) Ochi T, Iwase R, Kimura T, et al: Effect of early synovectomy on the course of rheumatoid arthritis. J Rheumatol 18: 1794-1798, 1991
PubMed
6) 君塚葵: 足の機能とバイオメカニクス. 関節外科13: 15-20, 1994
 
7) 牛山敏夫: 中足部の病態. リウマチ病セミナーVI (七川歡次監修), pp. 87-97, 大阪, 永井書店, 1995
 
8) 小松原良雄, 井澤一隆: 足関節固定術・距骨下関節固定術. 関節リウマチの手術療法 (平澤泰介編), pp. 159-168, 大阪, メジカルビュー社, 1994
 
9) Lance EM, Paval A, Fries I, et al: Arthrodesis of the ankle joint. Clin Orhop 142: 146-158, 1979
PubMed
10) Carrier DA, Harris CM: Ankle arthrodesis with vertical Steinmann's pins in rheumatoid arthritis. Clin Orthop Rel Res 268: 10-14, 1991
 
11) Moran CG, Pinder IM, Smith SR: Ankle arthrodesis in rheumatoid arthritis. Acta Orthop Scand in 62: 538-543, 1991
PubMed
P.264 掲載の参考文献
1) Gallie WE: Fractures and dislocations of the cervical spine. Am J Surg 46: 495-499, 1939
 
2) Rogers WA: Treatment of fracture-dislocation of the cervical spine. J Bone Joint Surg 24-A: 245-255, 1942
 
3) Caspar W, Barbier DD, Klara PM: Anterior cervical fusion and Caspar plate stabilization for cervical trauma. Neurosurgery 25: 491-502, 1989
PubMed
4) Suh PB, Kostuik JP, Esses SI: Anterior cervical plate fixation with the titanium hollow screw plate system. A preliminary report. Spine 15: 1079-1081, 1990
PubMed
5) Lowery GL: Anterior cervical osteosynthesis: OrionTM anterior cervical plate system. Technique in Spinal Fusion and Stabilization (Ed, Hitchon PW, Traynelis VC, Rengachary SS), pp. 191-197, New York, Thieme Medical Publishers, Inc, 1995
 
6) Mitsui H: A new operation for atlanto-axial arthrodesis. J Bone Joint Surg 66-B: 422-425, 1984
 
7) Magerl F, Seeman PS: Stable posterior fusion of the atlas and axis by transarticular screw fixation. Cervical Spine I (Ed, Kehr P, Weidner A), pp. 322-327, Wien, Springer. Verlag, 1987
 
8) Aebi M, Etter C, Coscia M: fractures of the odontoid process. Treatment with anterior screw fixation. Spine 14: 1065-1070, 1989
PubMed
9) 勝浦章知, 福田眞輔, 今中徹ら: RA頸椎病変に対する後頭骨-環軸椎固定術 (Brattstrom-Granholm変法)-長期成績と限界-. 日関外誌13: 255-262, 1994
 
10) Hukuda S, Katsuura A: Operations for subluxation of the cervical spine in patients with rheumatoid arthritis. A transition from short fusion to long fusion. Orthopaedics 2: 118-124, 1994
 
11) Katsuura A, Hukuda S, Imanaka T, et al: Anterior cervical plate used in degenerative disease can maintain cervical lordosis. J Spinal Disord, 1996 (in press)
 

書評

最近チェックした商品履歴

Loading...